{"companyId":366854,"requestedLanguage":"ja","resolvedLanguage":"ja","availableLanguages":["en","es","ja"],"companyName":"Oryzon Genomics, S.A.","headOfficeLocation":"サント・フェラン74番地、コルネリャ・デ・ロブレガット、08940、スペイン","presidentName":"カルロス・マヌエル・ブエサ・アルホ","companySummary":null,"stockCode":"ORY","currency":"EUR","capital":null,"sales":null,"employees":46,"employeesConsolidated":null,"humanCheck":false,"domains":["oryzon.com"],"businessContents":["エピジェネティクス創薬のバイオ医薬品事業（がん・中枢神経系疾患）"],"relations":[],"dataSources":[{"detailNumber":1,"url":"https://stockanalysis.com/quote/bme/ORY/company/","scoreAbout":60,"scoreBusiness":60,"scoreGroup":0,"scoreCustomer":0}]}